Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma

NCT05138458 is registered in ClinicalTrials.gov with Myeloid Therapeutics as lead sponsor.

NCT NCT05138458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05138458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
Lead sponsor
Myeloid Therapeutics
Phase
Phase 1/2
Overall status
Suspended
Start date
December 15, 2021
Completion date
October 31, 2025
Enrollment
40 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adoptive cellular immunotherapy, cell therapy, lymphoma, t-cell, cutaneous, lymphoma, t-cell, peripheral, mycosis fungoides